Table 4.
Univariate analysis of risk factors for active tuberculosis infection after anti-TNF therapy n (%)
| TB infection + (n = 16) | TB infection - (n = 360) | P value | |
| Age at anti-TNF (yr) | 26 (21-70) | 30 (11-76) | 0.808 |
| Female | 3 (18.8) | 118 (32.8) | 0.287 |
| Diseases | 0.772 | ||
| Crohn’s disease | 11 (68.8) | 266 (73.9) | |
| Ulcerative colitis | 5 (31.3) | 94 (26.1) | |
| Diabetes mellitus | 1 (6.3) | 11 (3.1) | 0.411 |
| Anti-TNF agent | 0.212 | ||
| Infliximab | 15 (93.8) | 279 (77.5) | |
| Adalimumab | 1 (6.3) | 81 (22.5) | |
| LTBI | 4 (25) | 26 (7.2) | 0.031 |
| IM at anti-TNF agent | 13 (81.3) | 228 (63.3) | 0.187 |
| WBC count < 5000 mm3 | 10 (62.5) | 115 (31.9) | 0.015 |
LTBI: Latent tuberculosis infection; IM: Immunomodulator.